Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
  • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/47—Quinolines; Isoquinolines
  • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
  • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
  • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
  • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
  • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
  • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
  • A61K9/1605—Excipients; Inactive ingredients
  • A61K9/1629—Organic macromolecular compounds
  • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
  • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
  • A61K9/1682—Processes
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
  • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
  • A61K9/1682—Processes
  • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
  • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
  • A61K9/1605—Excipients; Inactive ingredients
  • A61K9/1611—Inorganic compounds

Definitions

• the present invention is directed to oral drug complex microparticles containing: a pharmaceutical active having a nitrogen moiety and an anionic methacrylic acid copolymer; wherein the oral drug complex micropaticles resist dissolution or dissociation upon exposure to saliva, but which rapidly dissociate in gastric acid and which rapidly dissolve in intestinal fluid.
• the present invention is also directed to oral drug delivery devices containing said oral drug complex microparticles; processes for producing said oral drug complex microparticles and methods for treating patients including administering said oral drug delivery devices thereto.
• Liquid, syrups or suspensions are considered as desirable dosage forms for pediatric and geriatric patients.
• these dosage forms are often difficult to distribute, measure, dose and store due to the nature of dosage forms and problems with stability.
• fast-dissolving drug delivery systems such as fast melt tablets, effervescent tablets, lyophilized wafers and paper wafers etc.
• Fast dissolving drug delivery system can be manufactured by a variety of technologies, including direct compression, wet granulation, freeze drying and solvent coating.
• the most desired attributes of chewable tablets and fast-dissolving dosage forms are good taste and mouth feel.
• the dosage form should be bitterless, smooth and cooling in the mouth.
• the masking of unpleasant tastes is therefore an important consideration in the formulation of many therapeutic agents and can be achieved by several physical methods, barrier and complexation approaches, which are to minimize direct contact between the actives and the taste receptors in the oral cavity.
• Barrier approaches to mask the taste of unpalatable drugs involve preventing the drugs from contacting the taste buds by coating or encapsulating the drugs with inert materials such as sugars, natural or synthetic polymers, lipids or waxes. Microencapsulation of drug particles by polymers, lipids or waxes is the most common taste masking technique for chewable tablets and some fast dissolving dosage forms. Several methods and materials, which are well known in the art, have been used to coat drug particles and granules.
• Taste masking of bitter anionic and cationic drugs can be accomplished by complexing the drugs with either cation or anion exchange resins, respectively. Such approaches have been used in pharmaceutical industry in the effort of making bitterless active composition and palatable oral products.
• Neutral drugs can be adsorbed onto adsorbents such as silicon dioxide, magnesium trisilicate or magnesium aluminum silicate.
• oral drug complex microparticles are provided, containing: a pharmaceutical active having a nitrogen moiety and an anionic polymer containing acidic-reacting groups such as carboxylic, more preferably an anionic methacrylic acid copolymer such as Eudragit L 100-55, Eudragit L30 D-55, Eudragit L 100, Eudragit S 100, commercially available from Rohm America Inc, most preferably Eudragit L 100, most preferably an anionic methacrylic acid copolymer; wherein the oral drug complex micropaticles resist dissolution or dissociation upon exposure to saliva, but which rapidly dissociate in gastric acid and which rapidly dissolve in intestinal fluid.
• the oral drug complex microparticles exhibit an ionic strength of less than 102 mEq/liter, more preferrably less than 70 mEq/liter.
• the oral drug complex microparticles contain a pharmaceutical active having a nitrogen moiety selected from the group of acyclic amine, heterocyclic amine, amide, imine, imide and nitrile.
• the oral drug complex microparticles contain a pharmaceutical active selected from the group of Famotidine and Loratidine.
• the oral drug complex microparticles contain a pharmaceutical active having a nitrogen moiety and an anionic methacrylic acid copolymer, wherein pharmaceutical active and the anionic methacrylic acid copolymer are present in the oral drug complex microparticles in a ratio of 10:1 to 1:10, more preferably in a ratio of 3 : 1 to 1 :3; most preferably in a ratio of 1 : 1.
• the oral drug complex microparticles have a particle size of less than 50 ⁇ m; more preferably a particle size of less than 25 ⁇ m.
• the oral drug complex microparticles of the present invention may effectively mask the unpleasant tastes associated with many pharmaceutical actives and be incorporated into a variety of drug delivery devices including powders, chewable tablets, tablets, fast melt sugar tablets, lypholized wafers, quick dissolving paper wafers, mucoadhesive oral drug delivery films and non-mucoadhesive oral drug delivery films.
• oral drug delivery devices are provided containing oral drug complex microparticles, containing: a pharmaceutical active having a nitrogen moiety and an anionic polymer containing acidic- reacting groups such as carboxylic, more preferably an anionic methacrylic acid copolymer such as Eudragit L 100-55, Eudragit L30 D-55, Eudragit L 100, Eudragit S 100, commercially available from Rohm America Inc, most preferably Eudragit L 100, most preferably an anionic methacrylic acid copolymer; wherein the oral drug complex micropaticles resist dissolution or dissociation upon exposure to saliva, but which rapidly dissociate in gastric acid and which rapidly dissolve in intestinal fluid.
• the oral drug complex microparticles exhibit an ionic strength of less than 102 mEq/liter, more preferrably less than 70 mEq/liter.
• the oral drug delivery devices are provided in the form of a powder, a chewable tablet, a tablet, a fast melt sugar tablet, a lyophilized wafer, an intraoral paper wafer, a mucoadhesive film and a non-mucoadhesive film.
• the oral drug delivery devices may further contain stabilizers, taste modifying agents, preservatives, coloring agents, surfactant/wetting agents, plasticizers and water soluble film formers.
• the oral drug delivery devices may further contain a buffer, most preferrably a sodium bicarbonate buffer.
• the oral drug complex microparticles contain a pharmaceutical active having a nitrogen moiety selected from the group of acyclic amine, heterocyclic amine, amide, imine, imide and nitrile.
• the oral drug complex microparticles contain a pharmaceutical active selected from the group of Famotidine and Loratidine.
• the oral drug complex microparticles contain a pharmaceutical active having a nitrogen moiety and an anionic polymer containing acidic-reacting groups such as carboxylic, more preferably an anionic methacrylic acid copolymer such as Eudragit L 100-55, Eudragit L30 D-55, Eudragit L 100, Eudragit S 100, commercially available from Rohm America Inc, most preferably Eudragit L 100, most preferably an anionic methacrylic acid copolymer, wherein pharmaceutical active and the anionic polymer are present in the oral drug complex microparticles in a ratio of 10:1 to 1:10, more preferably in a ratio of 3:1 to 1:3; most preferably in a ratio of 1:1.
• an anionic polymer containing acidic-reacting groups such as carboxylic
• an anionic methacrylic acid copolymer such as Eudragit L 100-55, Eudragit L30 D-55, Eudragit L 100, Eudragit S 100, commercially available from Rohm America Inc, most
• the oral drug complex microparticles have a particle size of less than 50 ⁇ m; more preferably a particle size of less than 25 ⁇ m.
• the oral drug complex microparticles of the present invention preferably are water insoluble, bitterless and tasteless in the oral cavity, dissociate upon exposure to gastric fluids and dissolve in intestinal fluids.
• a process for producing oral drug complex microparticles including: (a) dissolving an anionic polymer, preferably a polymethylacrylate copolymer, in an alcohol or a hydro-alcoholic solution; (b) dissolving or suspending a pharmaceutical agent having a nitrogen moiety in a buffer solution; (c) simultaneously feeding the products of (a) and (b) into a high energy ultrasonic processor to produce a complex solution; (d) discharging the complex solution to a spray dryer for drying; and, (e) collecting the product oral drug complex microparticles.
• the process of the present invention preferably results in very limited to no degradation of the pharmaceutical active being processed.
• products of (a) and (b) are exposed to ultrasonic energy in (c) having a frequency between 25 and 40 kHz until a clear complex solution is produced.
• the ultrasonic energy may be generated by at least one of mechanical action and electromechanical action.
• a method for treating a patient including administering to the patient an oral drug delivery device containing oral drug complex microparticles, containing: a pharmaceutical active having a nitrogen moiety and an anionic polymer containing acidic-reacting groups such as carboxylic, more preferably an anionic methacrylic acid copolymer such as Eudragit L 100- 55, Eudragit L30 D-55, Eudragit L 100, Eudragit S 100, commercially available from Rohm America Inc, most preferably Eudragit L 100, preferably an anionic methacrylic acid copolymer; wherein the oral drug complex micropaticles resist dissolution or dissociation upon exposure to saliva, but which rapidly dissociate in gastric acid and which rapidly dissolve in intestinal fluid.
• the oral drug complex microparticles exhibit an ionic strength of less than 102 mEq/liter, more preferrably less than 70 mEq/liter.
• Figure 1 depicts the chemical structure of methyl methacrylate copolymers
• Figure 2 depicts the ionic interation of acidic polymer (Eudragit LI 00) and amine drugs
• Figure 3 depicts a preferred process of the invention for producing acidic polymer-basic drug microparticles
• Figure 4 is a graphical representation of the effect of pH on a preferred famotidine- polymer (Eudragit LI 00) complex of present invention
• Figure 5 is a graphical representation of the dissolution profiles in artificial saliva of the Famotidine containing oral drug complex microparticles discussed in Examples 1-3,
• Figure 6 is a graphical representation of the dissociation profiles in gastric fluid of the Famotidine containing oral drug complex microparticles discussed in Examples 1-3,
• Figure 7 is a graphical representation of the dissolution profiles in intestinal fluid of the Famotidine containing oral drug complex microparticles discussed in Examples 1-3, and
• Figure 8 is a graphical representation of the stability of some oral drug delivery devices of the present invention in the form of quick dissolving intraoral dosage films containing oral drug complex microparticles produced in accordance with Examples 1-3 herein.
• patient as used herein and in the appended claims is an animal, preferably a mammal, more preferably a human.
• the products and methods of the present invention provide a means for increasing the palatability of oral dosage forms. By increasing the palatability of such oral dosage forms, it is believed that patient compliance may be improved.
• the present invention provides oral drug complex microparticles for use in oral drug delivery systems.
• the oral drug complex microparticles provided by the present invention contain: a pharmaceutical active having a nitrogen moiety and an anionic polymer.
• the oral drug complex microparticles of the present invention preferably resist dissolution or dissociation upon exposure to saliva.
• the oral drug complex microparticles of the present invention preferably, rapidly dissociate in gastric acid and rapidly dissolve in intestinal fluid.
• the oral drug complex microparticles of the present invention may exhibit an ionic strength of less than 102 mEq/liter, more preferrably less than 70 mEq/liter.
• compositions suitable for use with the present invention include active agents having a nitrogen moiety selected from the group of acyclic amine, heterocyclic amine, amide, imine, imide and nitrile. More preferably, the pharmaceutical active may be selected from the group of Famotidine and Loratidine, most preferably Famotidine.
• Anionic polymers suitable for use with the present invention include anionic polymers containing acidic-reacting groups such as carboxylic, more preferably an anionic methacrylic acid copolymer such as Eudragit L 100-55, Eudragit L30 D-55, Eudragit L 100, Eudragit S 100, commercially available from Rohm America Inc, most preferably Eudragit L 100, most preferably an anionic methacrylic acid copolymer.
• the ratio of pharmaceutical active to anionic polymer in the oral drug complex micropaticles of the present invention may be in a ratio range of 10 : 1 to 1:10, more preferably in a ratio range of 3 : 1 to 1:3; most preferably in a ratio range of 1 : 1.
• the oral drug complex microparticles of the present invention preferably exhibit a particle size of less than 50 ⁇ m; more preferably a particle size of less than 25 ⁇ m.
• the present invention also provides oral drug delivery devices which contain oral drug complex microparticles of the present invention.
• Drug delivery devices suitable for use with the present invention include conventional oral delivery devices.
• oral delivery devices suitable for use with the present invention include powders, chewable tablets, oral tablets, fast melt sugar tablets, lyophilized wafers, intraoral paper wafers, mucoadhesive films and a non-mucoadhesive films, most preferably mucoadhesive and non- mucoadhesive films.
• the oral drug delivery devices of the present invention may optionally contain buffers, stabilizers, taste modifying agents, preservatives, coloring agents, surfactant/wetting agents, plasticizers and water soluble film formers.
• Buffers suitable for use with the present invention include, but are by no means limited to, citric acid, fumaric acid, lactic acid, tartaric acid, malic acid, sodium citrate, sodium bicarbonate, sodium carbonate, sodium phosphate, potassium phosphate and magnesium oxide, more preferably carbonated buffers, most preferably sodium bicarbonate buffers.
• Stabilizers suitable for use with the present invention include, but are by no means limited to, anti-oxidants, chelating agents and enzyme inhibitors.
• Preferred stabilizers include ascorbic acid, vitamin E, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), propyl gallate, dilauryl thiodipropionate, thiodipropionic acid, gum guaiac, citric acid, edetic acid and its salts and glutathione.
• taste modifying agents suitable for use with the present invention include, but are by no means limited to, flavoring agents, sweetening agents and taste masking agents.
• Preferred taste modifying agents include the essential oils or water soluble extracts of menthol, wintergreen, peppermint, sweet mint, spearmint, vanillin, cherry, chocolate, cinnamon, clove, lemon, orange, raspberry, rose, spice, violet, herbal, fruit, strawberry, grape, pineapple, peach, kiwi, papaya, mango, coconut, apple, coffee, plum, watermelon, nuts, durean, green tea, grapefruit, banana, butter, camomile, sugar, dextrose, lactose, mannitol, sucrose, xylitol, malitol, acesulfame potassium, talin, glycyrrhizin, sucralose, aspartame, saccharin, sodium saccharin, sodium cyclamate and honey.
• Preservatives suitable for use with the present invention include, but are by no means limited to, anti-microbial agents and non-organic compounds.
• Preferred preservatives include sodium benzoate, parabens and derivatives, sorbic acid and its salts, propionic acids and its salts, sulfur dioxide and sulfites, acetic acid and acetates, nitrites and nitrates.
• Coloring agents suitable for use with the present invention include, but are by no means limited to, FD & C coloring agents, natural coloring agents, natural juice concentrates and pigments.
• Preferred pigments include titanium oxide, silicon dioxide and zinc oxide.
• Surfactant wetting agents suitable for use with the present invention include, but are by no means limited to, poloxamer, polyoxyethylene alkyl ethers, polyoxyethylene castor oil derivatives, polyoxyethylene sorbitan fatty acid esters, polyoxyethylene stearates, sodium lauryl sulfate.
• Preferred surfactant/wetting agents include polyoxyethylene castor oil derivatives.
• Plasticizing agents suitable for use with the present invention include, but are by no means limited to, glycerin, sorbitol, propylene glycol, polyethylene glycol, triacetin, triethyl citrate (TEC), acetyl triethyl citrate (ATEC) and other citrate esters.
• Water soluble film formers suitable for use with the present invention include, but are by no means limited to, hydrocolloids, for example:
• Preferred water soluble film formers include hydroxypropyl methyl cellulose having a methoxy content of 19-30% and a hydroxypropyl content of 7 to 12% with a molecular weight of 50,000 to 250,000 daltons.
• the present invention also provides a process for producing the oral drug complex microparticles of the present invention.
• the process of the present invention includes (a) dissolving an anionic polymer, preferably a polymethylacrylate copolymer, in an alcohol or a hydro-alcoholic solution; (b) dissolving or suspending a pharmaceutical agent having a nitrogen moiety in a buffer solution; (c) simultaneously feeding the products of (a) and (b) into a high energy ultrasonic processor to produce a complex solution; (d) discharging the complex solution to a spray dryer for drying; and, (e) collecting the product oral drug complex microparticles.
• Figure 3 provides an illustration of a preferred embodiment of the process of the present invention wherein the anionic polymer (Eudragit L-100 commercially available from Rohm America, Inc.) is dissolved or dispersed in alcohol, the pharmaceutical active is Famotidine which is dissolved or dispersed in aqueous solution.
• the anionic polymer Eudragit L-100 commercially available from Rohm America, Inc.
• Famotidine Famotidine which is dissolved or dispersed in aqueous solution.
• the products of (a) and (b) are preferably exposed to ultrasonic energy in (c) having a frequency between 25 and 40 kHz until a clear complex solution is produced.
• the ultrasonic energy to which the products of (a) and (b) are subjected may preferably be generated using any conventional means, more preferably any conventional means using mechanical action or electromechanical action.
• the present invention also provides a method for treating patients including administering to the patient an oral drug delivery device containing oral drug complex microparticles of the present invention.
• Oral drug complex microparticles of the present invention were prepared having the formulations indicated in Table 1 according to the processes discussed in the following examples.
• An oral drug delivery device comprising bitterless Famotidine oral drug complex microparticals incorporated into a mucoadhesive intraoral film was prepared as follows:
• hydroxypropyl methylcellulose having a methoxy content of 29% hydroxypropyl content of 8.5% and a viscosity (2%) of 4-6 cps (namely Methocel E15 commercially available from Dow Chemical Company) was wetted and uniformly mixed and uniformly mixed with ethanol, peppermint and strawberry twist, propylene glycol and cremophore;
• the Famotidine and Eudragit L-100 microparticles were present in the product film at a 1 :2 ratio by weight to the sodium bicarbonate therein.
• Another oral drug delivery device comprising bitterless Famotidine oral drug complex microparticals incorporated into a mucoadhesive intraoral film was prepared as follows:
• hydroxypropyl methylcellulose having a methoxy content of 29% hydroxypropyl content of 8.5% and a viscosity (2%) of 4-6 cps (namely Methocel El 5 commercially available from Dow Chemical Company) was wetted and uniformly mixed and uniformly mixed with ethanol, peppermint and strawberry twist, 70% sorbitol solution and cremophore;
• the Famotidine and Eudragit L-100 microparticles are present in the product film at a 1 :2 ratio to the sodium bicarbonate therein.
• Another oral drug delivery device comprising bitterless Famotidine oral drug complex microparticals incorporated into a mucoadhesive intraoral film was prepared as follows:
• hydroxypropyl methylcellulose having a methoxy content of 29% hydroxypropyl content of 8.5% and a viscosity (2%) of 4-6 cps (namely Methocel El 5 commercially available from Dow Chemical Company) was wetted and uniformly mixed and uniformly mixed with ethanol, peppermint and strawberry twist, propylene glycol and cremophore;
• the Famotidine and Eudragit L-100 microparticles are present in the product film at a 1 :2 ratio to the sodium bicarbonate therein.
• An oral drug delivery device comprising bitterless Loratadine oral drug complex microparticals incorporated into a mucoadhesive intraoral film was prepared as follows:
• Sodium EDTA, Aspartame, Sunnett, Nipagin M/Nipasol M and FD&C Red 40 were completely dissolved in water to form a sweetening solution; (7) hydroxypropyl methylcellulose having a methoxy content of 29% hydroxypropyl content of 8.5% and a viscosity (2%) of 4-6 cps (namely Methocel E15 commercially available from Dow Chemical Company) was wetted and uniformly mixed and uniformly mixed with ethanol, peppermint and strawberry twist, 70% sorbitol solution, propylene glycol and cremophore;
• the Famotidine and Eudragit L-100 microparticles are present in the product film at a 1 :2 ratio to the sodium bicarbonate therein.
• the dissolution profiles in artificial saliva of the oral drug delivery devices obtained according to Examples 1-3 were determined using USP apparatus, in 900 mL of dissolution media of artificial saliva solution, at rotation of 50 rpm, with a constant temperature bath at 37 ⁇ 0.5°C.
• Four-milhhter samples were drawn at 0.5, 1, 2, 4, 1, 10, 20, 45 and 60 minutes, the dissolution samples were filtered with a 0.45 m f i lter prior to analysis.
• the dissolution profile data obtained are presented in graphical form in Figure 5.
• the dissolution profiles in gastric fluid of the oral drug delivery devices obtained according to Examples 1-3 were determined using USP apparatus, in 900 mL of dissolution media of simulated gastric acid, at rotation of 50 rpm, with a constant temperature bath at 37 ⁇ 0.5°C. Four-milliliter samples were drawn at 0.5, 1, 2, 4, 7, 10, 20, 45 and 60 minutes. The dissolution samples were filtered with a 0.45 ⁇ m filter prior to analysis. The dissolution profile data obtained are presented in graphical form in Figure 6.
• the dissolution profiles in intestinal fluid of the oral drug delivery devices obtained according to Examples 1-3 were determined using USP apparatus, in 900 mL of dissolution media of simulated intestinal fluid, at rotation of 50 rpm, with a constant temperature bath at 37 ⁇ 0.5°C. Four-milliliter samples were drawn at 0.5, 1, 2, 4, 1, 10, 20, 45 and 60 minutes. The dissolution samples were filtered with a 0.45 ⁇ m filter prior to analysis. The dissolution profile data obtained are presented in graphical form in Figure 7.
• Oral drug complex microparticles according to the present invention containing Fomatodine and Eudragit LI 00 (commercially available from Rohm America Inc.) at a 1 :1 ratio by weight.
• Buffer solutions with different pH from 2 to 7 were prepared by using 0.1 molar citric acid and 0.2 molar disodium phosphate.
• lOOmg of complex powder was added to 15 mL of each tested buffer solution, mixed well by rolling up to 2 hour. Before sampling, each sample was left to stand on the bench for about 5 minutes, then supernatant was drawn and filtered and analyzed by HPLC. The results of this analysis are presented in graphical form in Figure 4.
• the turbidity of oral drug complex microparticles was assessed in various ionic strength solutions having a pH of about 6.6.
• a stock buffer solution with pH about 6.6 and ionic strength of about 307 mmol/L was prepared by using monobasic and dibasic sodium phosphate.
• a series of buffer solutions with different ionic strength were made from the stock solution by diluting.
• About 9 mg of complex powder with Eudragit LlOO/Famotidine at a 2:1 ratio was added into each buffer solution, the mixtures were occasionally shaken gently to help the complex powder to disperse in the buffer solution. Five minutes later, the samples were placed on a roller until the complex powder was dissolved.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Veterinary Medicine (AREA)
• Chemical & Material Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Pharmacology & Pharmacy (AREA)
• Epidemiology (AREA)
• Medicinal Chemistry (AREA)
• Engineering & Computer Science (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Nutrition Science (AREA)
• Physiology (AREA)
• Inorganic Chemistry (AREA)
• Zoology (AREA)
• Medicinal Preparation (AREA)

Applications Claiming Priority (3)

Publications (1)

Family

ID=29250659

Family Applications (1)

Country Status (5)

Families Citing this family (26)

Family Cites Families (7)

• 2003
  • 2003-04-08 CA CA002480403A patent/CA2480403A1/en not_active Abandoned
  • 2003-04-08 AU AU2003224890A patent/AU2003224890A1/en not_active Abandoned
  • 2003-04-08 US US10/409,696 patent/US20040013731A1/en not_active Abandoned
  • 2003-04-08 EP EP03721583A patent/EP1496867A1/de not_active Withdrawn
  • 2003-04-08 WO PCT/US2003/010805 patent/WO2003086363A1/en not_active Application Discontinuation

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events